- Home
- Advocacy
- Latest News and Practice Data
- August Recess Rally: Over 1,100 Messages from the CAP Encourage Congress to Stop the FDA’s Final LDT Rule
More than 340 CAP members initially took action during our August Recess Rally and responded to a specific alert to stop the implementation of the Food and Drug Administration’s (FDA) final laboratory-developed test (LDT) rule. Over 1,100 messages were sent to members of Congress, including those from 29 CAP members who took action for the first time.
The CAP is urging Congress to enact legislation like the Verifying Accurate Leading-edge IVCT Development (VALID) Act before the end of the year. The VALID Act creates a tiered risk-based structure for oversight of LDTs, includes a targeted role for the FDA, and utilizes current laboratory reporting requirements when possible. Questions about FDA LDT oversight? Visit our Laboratory-Developed Test Oversight page.
Haven’t taken action yet? Click here to engage and advocate!